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Abstract
Background: Budesonide has a long history as intranasal drug, with many marketed products. Efforts should be made to
demonstrate the therapeutic equivalence and safety comparability between them. Given that systemic availability significantly
varies from formulations, the clinical comparability of diverse products comes to be of clinical interest and a regulatory
requirement. The aim of the present study was to compare the systemic availability, pharmacodynamic effect, and safety of two
intranasal budesonide formulations for the treatment of rhinitis.
Methods: Eighteen healthy volunteers participated in this randomised, controlled, crossover, clinical trial. On two separated
days, subjects received a single dose of 512 μg budesonide (4 puffs per nostril) from each of the assayed devices (Budesonida
nasal 64®, Aldo-Union, Spain and Rhinocort 64®, AstraZeneca, Spain). Budesonide availability was determined by the
measurement of budesonide plasma concentration. The pharmacodynamic effect on the hypothalamic-adrenal axis was
evaluated as both plasma and urine cortisol levels. Adverse events were tabulated and described. Budesonide availability
between formulations was compared by the calculation of 90%CI intervals of the ratios of the main pharmacokinetic parameters
describing budesonide bioavailability. Plasma cortisol concentration-time curves were compared by means of a GLM for
Repeated Measures. Urine cortisol excretion between formulations was compared through the Wilcoxon's test.
Results: All the enroled volunteers successfully completed the study. Pharmacokinetic parameters were comparable in terms
of AUCt (2.6 ± 1.5 vs 2.2 ± 0.7), AUCi (2.9 ± 1.5 vs 2.4 ± 0.7), tmax (0.4 ± 0.1 vs 0.4 ± 0.2), Cmax/AUCi (0.3 ± 0.1 vs 0.3 ± 0.0),
and MRT (5.0 ± 1.4 vs 4.5 ± 0.6), but not in the case of Cmax (0.9 ± 0.3 vs 0.7 ± 0.2) and t1/2 (3.7 ± 1.8 vs 2.9 ± 0.4). The
pharmacodynamic effects, measured as the effect over plasma and urine cortisol, were also comparables between both
formulations. No severe adverse events were reported and tolerance was comparable between formulations.
Conclusion: The systemic availability of intranasal budesonide was comparable for both formulations in terms of most
pharmacokinetic parameters. The pharmacodynamic effect on hypothalamic-pituitary-adrenal axis was also similar. Side effects
were scarce and equivalent between the two products. This methodology to compare different budesonide-containing devices
is reliable and easy to perform, and should be recommended for similar products intented to be marketed or already on the
market.
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Background
Topic intranasal corticosteroids are first-line therapy for
allergic and vasomotor rhinitis [1] and among them
budesonide is the most prescribed drug because of its
demonstrated efficacy and an unequivocal safety profile
[2]. These findings are due to its short half-life, tissue
retention, topical activity and rapid first-pass hepatic
metabolism. Although budesonide has a long history of
use as intranasal drug, with many reports confirming its
safety [3,4], and since there are many marketed products
containing budesonide, efforts should be made for the
benefit of patients to demonstrate the therapeutic equiva-
lence and safety comparability between them.
In fact, the most frequent side effects associated with the
use of topical budesonide are mainly local effects (such as
epistaxis, nasal itching and nasal dryness). However, the
most severe adverse effects (adrenal suppression, loss of
bone mass and other metabolic and immunologic effects)
[5,6] are related to the budesonide into the systemic
bloodstream, and is therefore considered to be an unde-
sirable effect in the case of topically acting treatments. Of
particular interest is the dose-dependent hypothalamic-
pituitary-adrenal axis suppression that occurs with sys-
temic administration of corticosteroids which could,
which is much less apparent with the intranasal adminis-
tration of budesonide.
In the case of intranasal corticosteroids, a high systemic
availability could be expected due to the abundant vascu-
larity of the nasal mucosa, and also due to direct absorp-
tion from the nasal mucosa which does not provide
hepatic first-pass inactivation. In addition, although mod-
ern devices deliver most of the administered dose to the
nasal mucosa, a percentage of the dose (up to a 50%) [7]
is transported by the mechanism of mucociliar clearance
to the gastrointestinal tract, where it is ingested and
absorbed into the systemic bloodstream.
The systemic bioavailability of nasal corticosteroids is
greatly influenced both by the vehicle and by the device
characteristics (determining the particle size and the per-
centage of deposition) [8,9], and therefore, a wide differ-
ence could be expected from different manufacturers.
Although pressurized aerosols were the first topical for-
mulation to deliver intranasal corticosteroids, over recent
years powder formulations and mainly, aqueous pump
sprays, are become the usual devices. Aqueous solutions
provide an adequate drug deposition in the nasal mucosa
and are not accompanied by propellant-associated prob-
lems [10].
Some authors [10] have previously demonstrated that sys-
temic availability significantly differs from distinc formu-
lations. Consequently, clinical demonstration of the
systemic availability of diverse pharmaceutical formula-
tions and devices becomes of clinical interest and a regu-
latory requirement. Furthermore, international guidelines
[11-13] have established that in the case of local products
for the treatment of allergic rhinitis, the systemic absorp-
tion and metabolism must be determined. However, sys-
temic availability assessment for locally acting nasal drugs
is technically complicated because the administered dose
is usually very low and the drug is deposited topically, at
the site of action, and its activity does not occur after sys-
temic absortion.
The aim of the present study was to compare the systemic
availability, pharmacodynamic effect, and tolerability of
two intranasal budesonide formulations for the treatment
of allergic or vasomotor rhinitis.
Methods
Design and ethics
The present clinical trial is a pharmacokinetic study to
evaluate systemic exposure for nasally-acting budesonide-
containing products, also including the pharmacody-
namic assessment for systemic absorption. The study
design was a single-centre, randomised, double-blind,
active-controlled, two-way crossover, human pharmacol-
ogy clinical trial in healthy volunteers.
The trial was designed taking into consideration specific
international guidelines [11-15] and was conducted in
accordance with the Declaration of Helsinki and the Prin-
ciples of Good Clinical Practice. The trial was reviewed
and approved by the local IEC/IRB (CEIC at Txagorritxu
Hospital) and subsequently authorised by the Spanish
Medicines Agency. Informed consent was obtained from
all the participants before the enrolment in the trial. The
trial was registered in the EudraCT database (EudraCT
number: 2005-003727-39).
Subjects
Screening was performed during the 4 weeks preceding
the first administration of treatment. Eighteen healthy
adult volunteers (10 male and 8 female; mean age 24
years, range 19–39 years) participated in this study at the
Clinical Trials Unit (Txagorritxu Hospital, Vitoria, Spain).
All of them were Caucasian and had normal body weight
and height. Prior to the study, medical history including
presence of any allergy or significant disease (cardiac,
hepatic, renal pulmonary, neurological, gastrointestinal
or haematological), physical examination, electrocardiog-
raphy, and routine laboratory tests (haematology, clinical
chemistry blood test and urinary analysis) were registered.
All subjects were negative for hepatitis B, hepatitis C and
HIV serology, drug abuse urinary test and pregnancy test
(the latter in the case of females). Subjects were not eligi-
ble if clinically or analytically relevant results were identi-Trials 2008, 9:34 http://www.trialsjournal.com/content/9/1/34
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fied. They were required to abstain from taking any drug,
smoking or consuming exciting beverages (including cof-
fee and tea) for two weeks prior to and during the study
period. No subject did withdraw from the study and all
the enrolled subjects completed the planned schedule.
Study products
Two different formulations of 64 μg/dose of Budesonide
suspension for nasal nebulisation were assayed (Formula-
tion A: Budesonida nasal 64®, Aldo-Union, Spain and For-
mulation B: Rhinocort 64®, AstraZeneca, Spain).
Following a randomised sequence, subjects received from
both devices a single dose of 512 μg budesonide (4 actua-
tions per nostril) on two different experimental days, sep-
arated by a washout period of at least one week. This
supratherapeutic dosing regimen was dispensed to pro-
duce a measurable budesonide plasma concentration for
estimation of bioavailability and calculation pharmacok-
inetic of parameters.
Subjects were allocated in experimental groups of 9 indi-
viduals. Each investigational day, study drug administra-
tion begun at 08:00 with the first volunteer and was
sequentially given at 4-minutes intervals under the inves-
tigator's direct surveillance. The total dosage was given to
each nostril alternatively as eight actuations at intervals of
20 seconds (total time of drug administration, 2 min and
40 s). Time zero for each dose was defined as the time
when the inhaler was first actuated.
All inhalers were primed prior to use in a separate room.
Before drug dispensation, the subject gently blew his or
her nose and afterwards, the subjects rinsed their mouth
with water to avoid pharyngeal absorption. Then they
remained in relative rest in a semi-recumbent position
with the head of the bed elevated at a 45-degree angle for
4 hours.
As part of the screening and before the participation into
the study, the subjects were instructed with a placebo on
the proper use of the devices and the correct technique of
inhalation. Subjects self-administered the treatments, but
to assure the compliance and the inhalation technique,
the investigator directly supervised this procedure.
Study development
Budesonide availability was determined by the measure-
ment of budesonide plasma concentration after drug
administration. Pharmacodynamic effect on the hypotha-
lamic-adrenal axis was evaluated both through the evalu-
ation of the plasma cortisol and through the comparison
of urine cortisol excretion.
Subjects were admitted to the Clinical Trials Unit the
evening before each experimental day, when another drug
test and pregnancy test (in females) were performed. The
next morning, a venous cannula was inserted into a fore-
arm vein and maintained during the session. Blood sam-
ples were obtained at times basal (prior to drug
administration), +10 min, +20 min, +30 min, +45 min,
+1 h, +2 h, +4 h, +6 h, +8 h, +10 h, and +12 h for budes-
onide measurement. In addition, plasma cortisol concen-
tration was also determined at times basal (clock time
extending from 08:00 to 08:32), +2 h, +4 h, +6 h, and +12
h.
For each blood sampling, the first 1.5 ml from the cannula
were discarded, then a volume of 8 ml was taken and
afterwards 1.5 ml of physiological saline serum were
infused to keep the line permeable until next extraction.
Urine samples were collected in individual flasks for 12 h
after drug administration, the diuresis was also noted and
aliquots for urinary cortisol determination were obtained.
Both plasma and urine samples were stored frozen at -
80°C until analysis. Subjects were required to fast for 10
h before and 4 h after dosing.
Tolerability assessment
Subjects remained under direct surveillance by the medi-
cal staff and safety was monitored throughout the study.
All potential adverse events were immediately recorded
on the case report form and subsequently evaluated. Vital
signs (blood pressure and heart rate) were also monitored
throughout the experimental session. In addition, analyt-
ical tolerance (haematology, clinical chemistry, and uria-
nalysis) was assessed at screening and at the end of the
trial.
Laboratory measurements
Plasma budesonide was quantified under Good Labora-
tory Practice by Liquid Chromatography with MS/MS
detection, with a limit of quantification (LoQ) of 0.05 ng/
ml (ACC GmbH, Germany). Plasma cortisol was quanti-
fied by ECLIA quimioluminescent immunoassay with a
LoQ of 0.018 μg/dL (E-170 Analyser, Roche, Spain) and
urinary cortisol by means of FPIA fluorescent immu-
noassay with a LoQ of 0.77 μg/dL (TDX/FLX Analyser,
Abbot, Spain) at Hospital Txagorritxu, Spain.
Statistical methods
Considering the intra-individual variability of budeso-
nide plasma levels, for detecting differences of 20%
between both formulations with a power of 80% and a
significance level of 0.05, and adjusting for a 10% of
potential drop-outs, a sample size of 18 subjects was
required.
Pharmacokinetic parameters describing budesonide bioa-
vailability in extent and rate were estimated by a non-
compartmental model and described as mean ± SD. TheTrials 2008, 9:34 http://www.trialsjournal.com/content/9/1/34
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maximum concentration (Cmax) and time to reach the
maximum concentration (tmax) were obtained directly
from the experimental data. The areas under the curve
(AUCt, from 0 to the last concentration) were calculated
using the linear trapezoidal method and extrapolate to
infinity (AUCi) using the following formula: AUCi  =
AUCt+Ct/λz. The parameter Cmax/AUCi was directly calcu-
lated from the data. Elimination half-life (t1/2) was calcu-
lated by linear regression using the slope of the terminal
segment of the curve of log-concentration versus time.
Mean residence time (MRT) extrapolated to infinity was
calculated using the formula MRT = Area under the
moment curve/AUC.
Budesonide availability between formulations was com-
pared by means of a bioequivalence approach. First a log-
transformation of the parameters (with the exception of
tmax) was performed, followed by a calculation of 90%
Confidence Interval for the ratio of the geometric means
for the parameters under consideration, after the adminis-
tration of each formulation. Considering the nature of the
trial and the sample size, a wider interval of 0.75–1.33
was a priori considered appropriate. The parameter tmax
was not included in this model because it was considered
that the drug absorption rate is better reflected [16] by the
parameter Cmax/AUCi, with the advantage that its analysis
is possible under this approach. Then, in the case of tmax,
the 90% Confidence Interval for the difference of the
means was calculated by the non-parametric Hauschke's
method.
Pharmacodynamic effect was evaluated through the meas-
urements of plasma cortisol (at times 0, 2, 4, 8 and 12 h)
and urinary cortisol excretion during the 12 h after drug
administration. The time-concentration curves of plasma
cortisol were first described and subsequently compared
by means of a General Linear Model for Repeated Meas-
ures procedure (SPSS®), with Time as within-subjects fac-
tor (5 levels) and Formulation as between-subjects factor
(2 levels). The parameter AUC was also calculated for
plasma cortisol and subsequently compared by means of
the non-parametric Wilcoxon's test for paired data. Urine
cortisol excretion between formulations was compared by
means of the Wilcoxon's test. Adverse events were tabu-
lated and described.
Results
All the eighteen normal volunteers who entered in the
study successfully completed the trial and none discontin-
ued.
Systemic availability of Budesonide
Concentration/time and log-concentration/time curves of
systemic budesonide availability are shown in Figure 1,
exhibiting the evident similarity of the plasma level pro-
files. Table 1 summarises the main pharmacokinetic
parameters describing the systemic absortion in extent
and rate.
Comparison between formulations was performed
through a bioequivalence approach as can be seen in
Table 2. Most of the parameters can be considered as
equivalent since they fall within the acceptance range a
priori  established of the 0.75–1.33 of 90% Confidence
Intervals, with the exception of Cmax and t1/2 that exhibited
a slight increase in the case of formulation A.
Pharmacodynamic effect
The systemic effect of budesonide was evaluated through
the evaluation of its effect over plasma and urine cortisol.
Mean ± SD plasma budesonide concentrations after the administration of Formulation A () or Formulation B () Figure 1
Mean ± SD plasma budesonide concentrations after the administration of Formulation A ( ) or Formulation B ( ). 
Left, Concentration/Time curve. Right, Log-concentration/Time curve.
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Figure 2 shows the plasma cortisol concentration/time
curve. No significant differences are shown when the
curves are analyzed, neither by means of a repeated meas-
ures model nor through AUC comparison (Formulation
A: 100.9 ± 20.0 mg/dl; Formulation B: 99.6 ± 27.6 mg/dl).
Table 3 shows the diuresis and cortisol excretion during
the 12 h after drug administration. No significant differ-
ences are seen between both formulations.
Tolerability
No serious adverse events occurred during the trial. A total
of 11 side-effects were considered and occurred in 7 of the
18 volunteers. In four of the subjects, events were
recorded with either formulation A and B. The most fre-
quently evidenced events were oropharyngeal dryness (2
cases with formulation A and 2 cases with formulation B)
and headache (1 case with formulation A and 2 cases with
B). Other occurrences were episodes of pharyngitis (for-
mulation A), pruritus (2 cases with formulation B) and
lymphopaenia (formulation B).
Discussion
Topical administration of corticosteroids is preferred over
systemic administration to localize their effect, reduce the
total dose required and to minimize side effects. The
present study evaluates the systemic availability, pharma-
codynamic effect and tolerance of two intranasal formula-
tions of budesonide. Systemic absorption can either occur
from the nasal mucosa, thereby reflecting the amount of
drug exerting the therapeutic effec, or from the gastroin-
testinal tract. Although intranasal budesonide is a locally
applied locally acting drug, investigation of systemic
availability is recommendable since the most important
side effects are associated with the undesirable pass of
budesonide from nasal mucosa (or gastric mucosa) to the
general circulation, and its effect mainly on the hypotha-
lamic-pituitary-adrenal axis suppression. This is of partic-
ular relevance in the case of budesonide, which is better
absorbed through the nasal mucosa than other corticos-
teroids (e.g., fluticasone or mometasone).
Many factors can influence the variability that would be
seen within dosing of budesonide in clinical practice,
comprinsing both inter-individual variability and inter-
products disparity. The rationale for investigating two dis-
tinc products is based in the broad difference in systemic
availability which can be expected from diverse manufac-
turers, due to either product excipients or device character-
istics. Since several different products are available on the
market and it is a common clinical practice to switch
between them, all marketed products should be com-
pared to preserve patient's safety. In vitro methods to eval-
uate nasal sprays or aerosols (e.g., the characterisation of
particle size distribution, plume geometry, etc.) have clear
advantages compare with in vivo (less variability, facility
to control), and are indispensable during the product
development to demonstrate equivalent performance.
Nevertheless, in addition to in vitro studies, clinical studies
are also essential to detect differences between products,
Mean ± SD plasma cortisol concentrations after the adminis- tration of Formulation A () or Formulation B () Figure 2
Mean ± SD plasma cortisol concentrations after the adminis-
tration of Formulation A ( ) or Formulation B 
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Table 1: Pharmacokinetic parameters (expressed as mean ± SD) after the intranasal administration of 512 μg budesonide
Cmax (ng/ml) AUCt (h*ng/ml) AUCi (h*ng/ml) tmax (h) Cmax/AUCi (ng/ml)/(h*ng/ml) t1/2 (h) MRT (h)
Formulation A 0.90 ± 0.33 2.61 ± 1.50 2.91 ± 1.54 0.43 ± 0.18 0.33 ± 0.10 3.79 ± 1.83 5.01 ± 1.40
Formulation B 0.77 ± 0.24 2.24 ± 0.78 2.46 ± 0.77 0.43 ± 0.25 0.32 ± 0.08 2.98 ± 0.42 4.57 ± 0.69
Table 2: Bioequivalence evaluation (expressed as 90%CI of the 
Ln-transformed ratio, except for tmax, which is expressed as 
90%CI of the untransformed differences)
Ratio 90%Confidence Interval
Ln(Cmax) 1.13 0.95 – 1.35
Ln(AUCt) 1.10 0.92 – 1.32
Ln(AUCi) 1.12 0.95 – 1.32
Ln(Cmax/AUCi) 1.01 0.89 – 1.14
Ln(t1/2) 1.18 1.02 – 1.37
Ln(MRT) 1.07 0.97 – 1.20
tmax 1.05 0.86 – 1.29Trials 2008, 9:34 http://www.trialsjournal.com/content/9/1/34
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especially due to the difficulties encountered in ade-
quately characterising drug particle size distribution [13].
Clinical studies can be carried out either in healthy volun-
teers or in allergic rhinitis patients. However, since the
effect of inflammation and swelling in the mucosal lining
of the nose on systemic availability in patients with rhin-
itis is unknown and could potentially increase the inter-
subjects variability, the study design with the enrolment
of healthy volunteers was considered the most appropri-
ate model [13]. Moreover, the systemic availability of
budesonide was previously evaluated in healthy subjects
by other authors [10].
In this clinical study, the main pharmacokinetic parame-
ters after a single dose of 512 μg budesonide given by two
different devices were estimated. Results were consistent
with previous communications by others [10], when a
similar Cmax of 0.43 ng/ml (0.99 nmol/l) was evidenced
after a single dose of 400 μg. Also, the rapid plasma clear-
ance is compatible with the expected rapid first-pass
hepatic metabolism.
In addition, the two products were compared in terms of
systemic bioavailability, pharmacodynamic effect and tol-
erance. Although pharmacokinetic parameters are exten-
sively described and the comparison is based on the
calculation of ratios and confidence intervals, this
research can not be considered a true bioequivalence as
for orally administered drugs, but a way to investigate the
systemic availability (and therefore, the likelihood of pro-
ducing systemic adverse events) of a locally-acting drug.
In this case, both products are revealed to be having a very
similar systemic exposure, in terms of extent and rate.
Only in two (Cmax and t1/2) out of seven pharmacokinetic
parameters analysed is the upper 90% confidence interval
slightly exceeded, even though this difference was not
reflected in the pharmacodynamic effect or in the toler-
ance, where no differences were revealed. Nevertheless, in
the case of highly variable products, wider acceptance
intervals are accepted, even 0.70–1.42, wider than the
assumed in our study [17].
Plasma levels were variable, as would be expected for
intranasally administered drugs. The high variability
found for those products can be elevated due to individ-
ual characteristics such as variations in nasal anatomy or
mucoliciar drainage. Another factor potentially contribut-
ing to the elevated variability is the possible alteration of
the drug deposition pattern because of the experimentally
higher volume admistered in this study, and the greater
loss of drug into the nasypharynx or externally from the
nasal cavity. What should also be considered is that the
relative scarce sample size also contributes to the presence
of a wider confidence interval. However, the most robust
parameters defining bioavailability (principally AUC, but
also MRT) are absolutely comparable between both for-
mulations and devices.
In accordance with international guidelines, in the case of
products for local use (such as nasal administration),
pharmacodynamic clinical studies are recommended in
addition to the clinical studies needed to investigate equi-
effectiveness. Adrenal suppression is the main pharmaco-
dynamic effect of corticoids and has been used as a marker
for the systemic bioactivity of topic corticosteroids [9]. In
the present study, adrenal suppression during drug expo-
sure was assessed by both plasma cortisol measurement
and 12-hour fractionated urine cortisol excretion. Both
products demonstrated analogous effect of plasma or
urine cortisol, but noteworthy is the fact that adrenal sup-
pression was minor, in spite of the high dose of budeso-
nide administered (512 μg), 4-fold higher than that
usually recommended for the clinical use (64 μg/nostril),
and it is an important safety finding. In addition, both for-
mulations were clinically and analytically well tolerated
and only minor discomfort episodes were reported, in
similar number and severity with both formulations.
Conclusion
A complete description of pharmacokinetics parameters
after a single dose of intranasal budesonide is given and
two different intranasal devices are compared in terms of
systemic budesonide availability, pharmacodynamic
effect and tolerance, concluding equivalence between
them. This methodology for comparing different budeso-
nide-containing devices is reliable and easy to perform,
and should, together with clinical efficacy studies, be rec-
ommended for all similar products intended to be mar-
keted or already on the market.
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